Carter to lead Fusion Energy Division at Oak Ridge National Laboratory
Oak Ridge National Laboratory researchers are taking fast charging for electric vehicles, or EVs, to new extremes. A team of battery scientists recently developed a lithium-ion battery material that not only recharges 80% of its capacity in 10
Tom Karnowski and Jordan Johnson of ORNL have been named chair and vice chair, respectively, of the East Tennessee section of the Institute of Electrical and Electronics Engineers, or IEEE.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
Outside the high-performance computing, or HPC, community, exascale may seem more like fodder for science fiction than a powerful tool for scientific research. Yet, when seen through the lens of real-world applications, exascale computing goes from ethereal concept to tangible reality with exceptional benefits.
A new nanoscience study led by a researcher at ORNL takes a big-picture look at how scientists study materials at the smallest scales.
Mike Huettel is a cyber technical professional. He also recently completed the 6-month Cyber Warfare Technician course for the United States Army, where he learned technical and tactical proficiency leadership in operations throughout the cyber domain.
Technologies developed by researchers at ORNL have received six 2023 R&D 100 Awards.
Researchers at the Department of Energy’s Oak Ridge National Laboratory are leading the way in understanding the effects of electrical faults in the modern U.S. power grid.
A group at the Department of Energy's Oak Ridge National Laboratory made a difference for local youth through hands-on projects that connected neutron science and engineering intuitively.
After a highly lauded research campaign that successfully redesigned a hepatitis C drug into one of the leading drug treatments for COVID-19, scientists at ORNL are now turning their drug design approach toward cancer.